Justin Virgin – Executive Director – Terrain Minerals (ASX:TMX) is a West Australian based minerals exploration company focused on the world class mineral provinces in Western Australia. Terrain is actively looking for opportunities within other states of Australia and internationally.
Copyright 2024 – Finance News Network
21 Dec 2023 - Dive into Laramide Resources' (ASX:LAM) uranium ventures with insights from Non-Executive Chairman John G Booth. He discusses flagship projects, grants and developments in Australia and the US.
31 Jan 2020 - Los Cerros Limited (ASX:LCL) Managing Director, Jason Stirbinskis, talks about the company's gold projects in Colombia, the potential for high grade porphyry despots and plans to advance drilling at its Chuscal target.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
24 Nov 2020 - Altech Chemicals Limited (ASX:ATC) Managing Director Iggy Tan provides an update on construction of the company's high purity alumina (HPA) processing plant in Malaysia, its funding plans for the next phase of construction, growing HPA applications and plans for a second HPA plant in Saxony, Germany.
29 Jul 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch introduces the company, discussing its recent capital raising and share purchase plan.
30 Sep 2019 - Symposium, Managing Director, Kerry Stevenson talks about the importance of gold in a diversified portfolio, its successful performance over the past 12 months and all that’s on offer at this year’s event, 24-26 October, Sydney Sofitel Wentworth.
17 Aug 2022 - WT Financial Group Limited (ASX:WTL) Founder and Managing Director Keith Cullen discusses the company's indicative results and the future of financial advice.
25 Feb 2020 - Noxopharm Limited (ASX:NOX) Chief Medical Officer, Dr Gisela Mautner, talks about results from the company's LuPIN trial in prostate cancer, evaluating its lead product candidate, Veyonda, in combination with 177Lu-PSMA-617, a radiopharmaceutical therapy, in 56 patients with late-stage prostate cancer.